2022 年第一季度报告 单位：元 币种：人民币 证券代码：688321 证券简称：微芯生物 深圳微芯生物科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |--------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同 期增减变动幅度 (%) | | 营业收入 | 104,479,337.72 | 38.74 | | 归属于上市公司股东 ...

Financial Performance - The company achieved a revenue growth of 59.74% year-on-year in 2021[15]. - The net profit attributable to shareholders for 2021 was ¥21,958,284.55, while the parent company reported a net profit of ¥72,893,330.19[7]. - The company reported a revenue of 1.2 billion RMB for the fiscal year 2021, representing a year-over-year growth of 15%[21]. - The company's operating revenue for 2021 was ¥430,449,990.57, representing a 59.74% increase compared to ¥269,469,784.74 in 2020[33]. - The net profit attributable to shareholders for 2021 was ¥21,958,284.55, a decrease of 29.27% from ¥31,045,971.89 in 2020[33]. - The net cash flow from operating activities for 2021 was ¥124,783,166.51, an increase of 33.29% compared to ¥93,619,221.86 in 2020[33]. - The company's total assets at the end of 2021 were ¥1,894,406,023.56, a 9.74% increase from ¥1,726,271,014.19 in 2020[33]. - The company reported a basic earnings per share of ¥0.0537 for 2021, down 29.06% from ¥0.0757 in 2020[35]. - The company’s quarterly revenue for Q4 2021 was ¥153,904,024.71, showing a strong performance compared to previous quarters[40]. - The company reported a net profit of 25,864,823.63 RMB for the period, with a significant increase compared to the previous period's profit of 25,475,248.63 RMB, reflecting a growth of approximately 1.53%[42]. Research and Development - The company plans to increase R&D investment in 2022 and will not distribute profits or increase capital reserves for the year 2021[7]. - The company launched its second original innovative drug, Siglecatin Sodium, and initiated key Phase III clinical studies for its third original drug, Sioronib[15]. - The establishment of the R&D product chain and lifecycle management has been further improved and deepened[15]. - Research and development expenses accounted for 54.44% of operating revenue in 2021, up from 50.94% in 2020[35]. - The company plans to increase its R&D budget by 30% in the upcoming fiscal year to support innovation[21]. - The company has invested 200 million RMB in new technology for drug development, focusing on precision medicine[21]. - The company is actively developing a pipeline of over 20 new molecular entities, including CS271011, CS23546, and CS32582[56]. - The company has established an integrated drug discovery and early evaluation platform based on chemical genomics, which helps select compounds with the best comprehensive evaluation indicators for later development, reducing the risk of late-stage drug development[128]. - The company has a strong R&D team with 31 PhD holders and 80 master's degree holders, enhancing its competitive edge in drug development[119]. - The company has a rich pipeline of projects in development, indicating strong potential for future growth and market expansion[128]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, with plans to establish partnerships with local distributors by the end of 2022[21]. - The company aims to leverage national policies supporting technological innovation and capital market support for "hard tech" enterprises in its international development strategy[17]. - The company is committed to sustainable development in the biopharmaceutical sector, integrating early research, clinical development, and market access strategies[46]. - The company is actively engaged in expanding its market presence and enhancing its research and development capabilities to compete with multinational pharmaceutical companies[85]. - The company has established a commercial and market access department to manage distributors and sales contracts effectively[79]. Clinical Trials and Drug Development - The company is advancing four Phase III clinical trials for three major products, which are crucial for ensuring the commercialization of research outcomes and supporting future revenue growth[50]. - The company has received regulatory approval for three new drug applications, expected to boost future revenues significantly[21]. - The clinical trial for CS12192, a selective JAK3 inhibitor, has received FDA approval and is in the initiation phase[56]. - The company has initiated clinical trials for new drugs, including the III phase trial for Xioroni in small cell lung cancer, with FDA approval obtained for related trials[149]. - The company is conducting clinical trials for Xioroni in advanced triple-negative breast cancer patients who have failed anthracycline and taxane treatments, with approval received in July 2021[200]. - The company has submitted multiple clinical trial applications for various indications, including rheumatoid arthritis and non-small cell lung cancer, with approvals received throughout 2021[200]. Challenges and Risks - The company anticipates challenges in balancing long-term development goals with short-term expectations as it continues to grow[17]. - The company faces risks related to significant R&D investments, with potential delays in clinical trials and regulatory approvals impacting future revenue generation[135]. - The company has a high customer concentration risk, with the top five customers accounting for 81.67% of total revenue, which could affect stability if any major customer faces adverse changes[146]. - The company is at risk of insufficient funding for future R&D projects if revenue growth does not meet expectations or if government subsidies decrease[148]. - Regulatory changes in the biopharmaceutical industry could increase operational risks for the company, affecting various aspects of its business[153]. Innovation and Patents - The company has received FDA orphan drug designation for Xioloni for the treatment of small cell lung cancer in September 2021[88]. - The company has accumulated a total of 407 invention patents globally, with 123 granted as of December 31, 2021[98]. - In 2021, the company applied for 126 new invention patents and received 32 authorizations domestically and internationally[100]. - The company has implemented a comprehensive patent layout to prevent competition from generic drugs in the future[98]. - The company has successfully obtained patents for its drug discoveries, including a gold medal from the State Intellectual Property Office of China for Chidamide[67].

2021 年第三季度报告 单位：元 币种：人民币 证券代码：688321 证券简称：微芯生物 深圳微芯生物科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|----------------------------------------|----------------|---------------------------- ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2021, representing a 20% increase compared to the same period last year[2]. - The company's revenue for the first half of 2021 was ¥183,307,290.44, representing a 65.75% increase compared to ¥110,589,665.18 in the same period last year[27]. - The net profit attributable to shareholders was -¥7,152,330.88, a decrease of 124.91% from ¥28,711,659.31 in the previous year[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥14,797,302.70, down 195.00% from ¥15,575,672.30 year-on-year[27]. - The net cash flow from operating activities was ¥17,695,154.24, a decline of 69.34% compared to ¥57,717,172.76 in the same period last year[27]. - Cash and cash equivalents at the end of the period amounted to 351,701,960.01, representing 18.95% of total assets, an increase of 10.35% compared to the previous year[99]. - The company reported a net loss of -2,206,811.16, compared to an undistributed profit of 4,945,519.72 in the previous year, reflecting a decline of 144.62%[101]. Research and Development - Research and development expenses increased by 30% year-on-year, totaling 150 million RMB, reflecting the company's commitment to innovation[2]. - The R&D expenditure accounted for 55.56% of the revenue, an increase of 2.12 percentage points compared to 53.44% in the previous year[27]. - R&D investment totaled approximately ¥101.85 million, representing a year-over-year increase of 72.35%[48]. - The company has nearly 20 candidate drug projects, including CS17919, CS27109, and CS23546, currently undergoing preclinical and early exploratory research[36]. - The company has established a reputation and social influence in the innovative drug industry, supported by 20 years of continuous R&D investment[40]. - The company has a strong focus on innovative drug development, with several new molecular entities already approved for clinical use[33]. Product Development and Pipeline - A new product line is set to launch in Q4 2021, anticipated to contribute an additional 100 million RMB in revenue[2]. - The company focuses on original drug research in five major areas: oncology, metabolic diseases, autoimmune diseases, antiviral fields, and central nervous system disorders[33]. - The drug Chidamide has benefited nearly 10,000 lymphoma and breast cancer patients, with cumulative sales reaching nearly 10 million RMB and over 50,000 boxes provided for free[33]. - The company has 11 indications currently in clinical development and nearly 20 projects at different stages of exploratory research[33]. - The company aims to expand the indications for Chidamide as clinical trials progress, potentially leading to long-term sales growth[33]. - The company has established a comprehensive product chain covering innovative drugs from early development to clinical stages[33]. Market Strategy and Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[2]. - The company expects a revenue growth forecast of 25% for the second half of 2021, driven by new product launches and market expansion strategies[2]. - The company has established a modern and standardized management control system, enhancing operational efficiency across production, procurement, and research[71]. - The marketing network covers the entire country, with specialized divisions for oncology and metabolic disease products, supported by a team with extensive medical marketing experience[71]. Financial Integrity and Governance - No significant non-operational fund usage by controlling shareholders was reported, ensuring financial integrity[9]. - The company has committed to stabilizing its stock price and has fulfilled this commitment[132]. - The company has made commitments to not seek control over the company by certain shareholders[132]. - The company has established a plan to address the dilution of immediate returns[132]. - The company has not reported any significant changes in the status of its stock incentive plans since the last announcement[124]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[5]. - The company is facing risks related to the failure of new drug development and potential delays in clinical trials due to regulatory challenges[89]. - The increase in management expenses by 92.82% to ¥34,581,387.50 was mainly due to rising personnel costs and share-based payments[90]. Human Resources and Talent Development - The number of R&D personnel increased to 221, up from 131, representing 27.25% of the total workforce compared to 25.69% previously[61]. - Total compensation for R&D personnel reached ¥25,614,045.40, a significant increase from ¥13,131,960.00 in the previous period[61]. - The company has implemented a "100-person plan" to cultivate management talent, successfully training over 90 management reserve talents in two years[84]. Environmental and Social Responsibility - The environmental permit for the company was renewed, effective from June 21, 2021, to June 20, 2026[128]. - The company has implemented measures to establish an environmental protection system and emergency response plans for environmental incidents[129].

2021 年第一季度报告 公司代码：688321 公司简称：微芯生物 深圳微芯生物科技股份有限公司 2021 年第一季度报告 1 / 22 2021 年第一季度报告 重要提示 一、 二、 公司基本情况 三、 重要事项 四、 附录 目录 2 / 22 2021 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人 XIANPING LU、主管会计工作负责人黎建勋及会计机构负责人（会计主管人员） 左惠萍保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-------------------------------------------------|------------------|----------------------|---------------- ...

Financial Performance - The net profit attributable to shareholders for 2020 was CNY 31,045,971.89, while the parent company achieved a net profit of CNY 43,692,898.33[7]. - In 2020, the company's operating revenue increased by 55.05% year-on-year, reaching ¥269,469,784.74, primarily due to the significant sales growth of Xidabengamine[33]. - The net profit attributable to shareholders rose by 59.85% year-on-year to ¥31,045,971.89, driven by the increase in operating revenue[33]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 59.59% to ¥5,570,723.26, mainly due to increased R&D expenses and the use of government R&D funds[33]. - Basic earnings per share increased by 46.71% to ¥0.0757, reflecting the rise in net profit attributable to shareholders[33]. - The company's total assets at the end of 2020 were ¥1,726,271,014.19, a 2.06% increase from the previous year[30]. - The net assets attributable to shareholders increased by 3.28% to ¥1,493,829,887.04 at the end of 2020[30]. - The net cash flow from operating activities was ¥93,619,221.86, a significant recovery from a negative cash flow of ¥24,553,118.03 in 2019[30]. - The company's operating revenue for the reporting period was ¥269,469,784.74, representing a 55.05% increase compared to ¥173,800,400.62 in the previous year[147]. - The cost of sales increased by 84.85% to ¥13,475,128.14 from ¥7,289,600.22 in the previous year[147]. - The sales revenue from the main product, Sidabone, was ¥245,026,634.74, with a gross margin of 94.50%, down 1.37 percentage points from the previous year[148]. - The company reported a significant increase in R&D expenses, which rose by 79.40% to ¥92,290,557.52, indicating a strong focus on innovation[147]. Research and Development - The company plans to increase R&D investment in 2021, leading to no cash dividends or stock bonuses for the 2020 fiscal year[7]. - R&D investment accounted for 50.94% of operating revenue, an increase of 5.92 percentage points compared to the previous year[30]. - The total R&D investment for the year reached ¥137,264,542.12, a 75.44% increase compared to the previous year[95]. - The company has applied for a total of 281 invention patents, of which 91 have been authorized, showcasing its strong intellectual property portfolio in the innovative drug sector[76]. - The company has a complete innovative drug R&D capability, with all in-development drugs being new molecular entities[76]. - The company has established a comprehensive risk control strategy for clinical development based on scientific principles and mechanisms of action, which is crucial for navigating the complexities of drug development[82]. - The company’s research and development efforts are aimed at addressing critical issues faced by drug development enterprises, thereby increasing the likelihood of successful new drug development[82]. - The company has a strong focus on precision medicine strategies in its early candidate drug screening process[109]. - The company has a strong pipeline of innovative drug candidates with high originality and potential market value, supported by extensive experience in original drug research and development[112]. - The company has received IND approval for multiple Phase III trials, indicating progress towards market approval for several drugs[98]. Clinical Trials and Drug Development - The company has successfully developed innovative drugs, including Chidamide, which has benefited nearly 10,000 lymphoma patients with cumulative sales exceeding 820 million yuan[43]. - The Phase III clinical trial for Chidamide combined with the R-CHOP regimen for treating newly diagnosed MYC/BCL2 double-expressing diffuse large B-cell lymphoma (DLBCL) commenced in May 2020 with the first patient enrolled[86]. - The Phase III clinical trial for Chiglitazar combined with metformin for type 2 diabetes patients, who are inadequately controlled on metformin alone, received clinical trial approval in October 2020 and is currently in the initiation phase[86]. - The company has multiple drug candidates in various stages of clinical development, including CS12192, which received clinical trial approval in June 2020 and has completed the dose escalation for the Phase I trial[86]. - The company is conducting a Phase III clinical trial for Xigletan sodium, with a total expected investment of ¥15,000.00 million and ¥11,816.16 million cumulatively invested[98]. - The company has completed Phase II trials for Xigletan sodium in combination with metformin for Type 2 diabetes, with ongoing Phase III trials[100]. - The company has established a comprehensive drug discovery and early evaluation platform based on chemical genomics, which helps select compounds with the best comprehensive evaluation indicators for later development stages[109]. - The company is actively developing new drugs for non-small cell lung cancer, with multiple targeted kinase inhibitors approved, including Afatinib and Osimertinib, and ongoing research into KRAS inhibitors[80]. - The company has received regulatory acceptance for its investigational new drug applications (IND) for several candidates, indicating progress in its clinical development efforts[86]. - The company has a robust clinical trial pipeline, with several projects at different stages, ensuring a continuous supply of innovative drugs to meet clinical needs[112]. Market and Competitive Landscape - The global pharmaceutical market is projected to reach $1,500 billion by 2021, with the global innovative drug market expected to reach $978.7 billion[53]. - The global pharmaceutical expenditure for cancer treatment reached $75.3 billion in 2016, with a projected compound annual growth rate (CAGR) of 9-12%, expecting to reach $120-130 billion by 2021[56]. - The number of cancer patients globally is expected to grow at a rate of 6-9% from 2016 to 2021, with total cancer treatment costs projected to reach $147 billion by 2021[59]. - In China, the market share of targeted drugs is rapidly increasing, expected to become the largest category in the anti-cancer drug market within 3 to 5 years[60]. - The company has been operational for 20 years and continuously updates its technology based on advancements in life sciences and drug development[43]. - The company has established a strong reputation and social influence in the innovative drug industry, supported by 20 years of continuous R&D investment[76]. - The company aims to achieve global leadership in the treatment of various cancers and diabetes through its innovative drug development[106]. - The company has been recognized for its contributions to the pharmaceutical industry, receiving multiple awards for innovation and growth in recent years[112]. Corporate Governance and Compliance - The audit report issued by KPMG was a standard unqualified opinion, ensuring the accuracy of the financial statements[6]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures regarding external guarantees[11]. - The company has not disclosed any special arrangements for corporate governance[11]. - The company has a dedicated board secretary for information disclosure, ensuring compliance with regulatory requirements[24]. - The company’s financial disclosures are published in major Chinese financial newspapers and on the designated website of the China Securities Regulatory Commission[24]. - The company emphasizes quality management to mitigate risks associated with drug safety and compliance with stringent regulatory requirements[141]. Strategic Initiatives and Future Plans - The company plans to apply for IND for several promising candidates, including CS27109 and CS23546, in 2021, targeting high cholesterol and non-alcoholic fatty liver disease[121]. - The company aims to optimize its innovative drug sales team and model to better meet patient needs, with strategic adjustments to the sales management system based on market demand[125]. - The company has established a quality management system at the group level to ensure speed, quality, and medical risk control capabilities in drug development[124]. - The company is focusing on major diseases and market opportunities, aiming to provide differentiated clinical candidates that meet urgent patient needs[124]. - The company has established a new business unit for metabolic disease products to prepare for the launch of the diabetes product, Siglitazone, in collaboration with Zhejiang Hai Zheng Pharmaceutical Co., Ltd[127].

2020 年第三季度报告 公司代码：688321 公司简称：微芯生物 深圳微芯生物科技股份有限公司 2020 年第三季度报告 1 / 24 2020 年第三季度报告 一、 重要提示 二、 公司基本情况 11[ 重要事项 四、 附录 目录 2 / 24 2020 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人 XIANPING LU、主管会计工作负责人黎建勋及会计机构负责人（会计主管人员） 左惠萍保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------------------------|------------------------------|---------------------------- ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2020, representing a year-on-year increase of 20%[2]. - The company has projected a revenue guidance of 1.2 billion CNY for the full year 2020, indicating an expected growth of 25%[2]. - The company's revenue for the first half of 2020 reached ¥110,589,665.18, representing a 35.00% increase compared to the same period last year[22]. - Net profit attributable to shareholders increased by 63.97% to ¥28,711,659.31, driven by revenue growth and increased government subsidies[23]. - Basic earnings per share rose by 44.03% to ¥0.0700, reflecting the increase in net profit attributable to shareholders[22]. - The net cash flow from operating activities was ¥57,717,172.76, a significant recovery from a negative cash flow in the previous year[22]. - The company reported a significant increase in sales and marketing expenses by 71.48% to ¥46,214,219.43, attributed to academic promotion for new indications[82]. - The company achieved revenue of 110 million yuan in the first half of 2020, a 35% increase compared to the same period last year[69]. Research and Development - The R&D expenses for the first half of 2020 amounted to 100 million CNY, accounting for 20% of total revenue[2]. - Research and development expenses accounted for 53.44% of revenue, an increase of 14.50 percentage points year-on-year[22]. - The company achieved a total R&D investment of ¥59,093,742.58, which represents 53.44% of its operating revenue[53]. - The company’s R&D efforts are focused on five therapeutic areas: metabolic diseases, autoimmune diseases, tumors, central nervous system disorders, and antiviral treatments[50]. - The company has a robust pipeline of new molecular entities, including candidates CS17919, CS24123, and CS27100, which are in preclinical and early exploratory research stages[30]. - The company is conducting Phase III clinical trials for Epidaza® in diffuse large B-cell lymphoma and Phase II/III trials in non-small cell lung cancer[30]. - The company has a strong R&D team with 18 PhDs and 29 Master's degree holders, contributing to its competitive edge in drug development[61]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2021[2]. - A new product line is set to launch in Q3 2020, expected to contribute an additional 200 million CNY in revenue[2]. - The company is actively seeking partnerships for new drug introductions in oncology, metabolic diseases, autoimmune diseases, and antiviral fields[72]. - The company plans to establish a subsidiary in Beijing to enhance clinical research team organization and management capabilities[69]. - The company is exploring new markets for expansion, particularly in emerging economies, to capture additional growth opportunities[176]. Shareholder and Governance - The board has approved a share buyback program of up to 50 million CNY to enhance shareholder value[2]. - The company has committed to not reducing shareholdings during significant legal violations that could lead to delisting, ensuring stability in operations[102]. - Major shareholders, including BOAO Biology, have also agreed to similar lock-up commitments to maintain control and stability post-IPO[102]. - The company has outlined measures to repurchase shares to offset dilution effects, indicating a proactive approach to shareholder value[102]. - The company has established measures to compensate investors for losses incurred due to unfulfilled commitments, enhancing investor confidence[127]. Compliance and Risk Management - The company has maintained a strict compliance with laws and regulations, ensuring no instances of dishonesty or failure to fulfill court judgments[133]. - The company has established a comprehensive environmental protection system for its main product, Sidabenamine, which includes pollution management and emergency response plans[146]. - The company has implemented a restricted stock incentive plan in 2020, details of which are available in the public announcement[134]. - The company has no significant changes in the audit report status from the previous year[131]. - The company is focused on maintaining a competitive edge by avoiding conflicts of interest and ensuring compliance with all regulatory obligations[126]. Product Development and Innovation - The company has developed a series of innovative drugs, including Epidaza® (sydanib), which has generated over RMB 600 million in sales and has benefited nearly 10,000 lymphoma patients[30]. - The new drug, Seglitazone, is expected to be a comprehensive treatment for Type 2 diabetes and is currently under review for market approval[30]. - The company is advancing clinical trials for its innovative drug CS12192, a selective JAK3 inhibitor, which is currently in Phase I trials for rheumatoid arthritis[30]. - The company has a unique mechanism for JAK3 inhibitors, differentiating its application value from existing drugs[56]. - The company has a strong focus on quality management and compliance with international standards in clinical trials[67]. Financial Position and Assets - The total assets amounted to ¥1,685,109,796.60, showing a slight decrease of 0.37% compared to the end of the previous year[22]. - The company’s net assets attributable to shareholders at the end of the reporting period were ¥1,477,668,541.60, a 2.17% increase from the previous year[22]. - Cash and cash equivalents increased by 118.68% to ¥342,189,886.33, accounting for 20.31% of total assets[87]. - Inventory rose by 33.20% to ¥12,389,390.35, driven by increased sales of Sidabenamine and higher stock of raw materials[87]. - The company has two wholly-owned subsidiaries focused on drug development and production, with a registered capital of ¥60 million and ¥10 million respectively[92].

2020 年第一季度报告 公司代码：688321 公司简称：微芯生物 深圳微芯生物科技股份有限公司 2020 年第一季度报告 1 / 22 2020 年第一季度报告 重要提示 . 一、 二、 公司基本情况 . 11Í 重要事项 . 四、 附录 . 目录 2 / 22 2020 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人 XIANPING LU、主管会计工作负责人黎建勋及会计机构负责人（会计主管人员） 左惠萍保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |------------------------------------------------|------------------|-----------------------|------- ...

Financial Performance - The company achieved a net profit attributable to shareholders of 19,421,886.44 CNY for the year 2019, while the parent company reported a net profit of 21,287,298.15 CNY[7]. - As of December 31, 2019, the parent company's undistributed profits amounted to 37,977,835.45 CNY, whereas the consolidated undistributed profits were -21,731,162.34 CNY[7]. - Due to negative consolidated undistributed profits at the end of 2019, the company plans not to distribute cash dividends or issue bonus shares for the year[7]. - The company reported a significant increase in revenue, reaching 1.2 billion RMB, representing a 25% year-over-year growth[20]. - In 2019, the company's operating revenue increased by 17.68% year-on-year, reaching ¥173,800,400.62, while net profit attributable to shareholders decreased by 37.68% to ¥19,421,886.44[28]. - The net profit after deducting non-recurring gains and losses fell by 23.06% to ¥13,786,049.47, primarily due to rapid growth in selling and R&D expenses[28]. - The company's total assets grew by 136.12% year-on-year to ¥1,691,422,545.15, and net assets attributable to shareholders increased by 203.28% to ¥1,446,326,740.16, mainly due to funds raised from the IPO[28]. - Basic earnings per share decreased by 40.42% to ¥0.0516, and the weighted average return on net assets dropped by 4.29 percentage points to 2.41%[31]. - The company experienced a net cash flow from operating activities of -¥24,553,118.03 for the year, a decline of 207.77% compared to the previous year[28]. - The company recorded non-recurring gains of ¥5,866,841.31 from government subsidies closely related to its normal business operations[33]. Research and Development - The company plans to invest 200 million RMB in new technology development over the next two years[20]. - The R&D expenditure increased by 15%, totaling 300 million RMB, reflecting the company's commitment to innovation[20]. - R&D expenditure accounted for 45.02% of operating revenue, a decrease of 10.83 percentage points compared to the previous year[28]. - The company has a complete R&D, procurement, production, and sales system, ensuring a modern biopharmaceutical operational model[42]. - The drug development process includes early exploratory research, preclinical studies, and clinical trials, ensuring rigorous evaluation and compliance with regulatory standards[44]. - The company has established a supplier evaluation system to ensure the quality of materials used in drug production, adhering to GMP standards[42]. - The company has a strong R&D team with 106 personnel, including 11 PhDs and 84 with master's or bachelor's degrees, enhancing its drug development capabilities[79]. - The company has completed two Phase III clinical trials for Siglecin, with plans to submit a New Drug Registration Application (NDA) for Type 2 diabetes indication[74]. - The company has multiple ongoing Phase II clinical trials for its innovative drug, Xioroni, and several new molecular entity candidates in early exploratory research, indicating a robust pipeline[88]. Market Strategy and Expansion - The company is expanding its market presence in Southeast Asia, aiming for a 10% market share by the end of the next fiscal year[20]. - The company has initiated a new marketing strategy focusing on digital channels, aiming to increase brand awareness by 30%[20]. - The company plans to establish offices in 30 cities, including Beijing, Shanghai, and Shenzhen, to expand its marketing network and meet increasing market demand[197]. - The company aims to improve its product line through efficient data analysis and market demand orientation in drug development[169]. - The company is committed to internationalizing its innovative drugs, particularly by advancing overseas clinical trials for its products[169]. Corporate Governance and Compliance - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[10]. - The company has not disclosed any special arrangements for corporate governance[7]. - The company has established a clear framework for shareholding commitments to ensure compliance and transparency[184]. - The company has committed to a share lock-up period of 36 months from the date of listing on the Shanghai Stock Exchange, during which no shares will be transferred or repurchased[2]. Risks and Challenges - The company has outlined potential risks in its report, advising investors to be cautious in their investment decisions[5]. - The company faces risks related to the competitive landscape for diabetes treatment drugs, which may impact sales revenue if Siglitazone does not receive market approval or faces intensified competition[89]. - The company has identified risks associated with the unpredictability of clinical trial outcomes, which could delay or prevent commercialization of its drug candidates[93]. - The company is exposed to risks associated with conducting business overseas, including regulatory and economic factors[96]. Product Development and Innovation - The company focuses on innovative drugs for severe health threats such as malignant tumors and metabolic diseases, aiming to provide affordable and clinically needed medications[41]. - The main product, Epidaza® (Sida Benamide), is a first-class innovative drug approved in China, with cumulative sales exceeding 500 million RMB and benefiting nearly 10,000 lymphoma patients[41]. - The new drug, Seglitazone, is expected to be a comprehensive treatment for Type 2 diabetes and has been accepted for new drug application since September 2019[41]. - The company has established a management system for raised funds to ensure proper usage and compliance with legal regulations[194]. - The company aims to develop innovative drugs with novel mechanisms and clinical differentiation, utilizing a platform based on chemical genomics for early drug discovery and evaluation[166].